The Biosimilars Market is estimated to be valued at US$ 5.0 billion in 2017 and is expected to exhibit a CAGR of 35.2% over the forecast period 2018-2026, as highlighted in a new report published by Coherent Market Insights.
The biosimilars market refers to the market for pharmaceutical products that are highly similar to a reference biologic drug and have no clinically meaningful differences in terms of safety, efficacy, and quality. These products are developed and approved following a stringent regulatory process to prove their similarity to the reference biologic drug. Biosimilars are an affordable alternative to expensive biologics, offering significant cost savings to patients and healthcare organizations.
Biosimilars find applications across various therapeutic areas, including oncology, autoimmune diseases, diabetes, and infectious diseases. They are used to treat a wide range of chronic conditions and are known for their efficacy in managing these diseases. The market for biosimilars is driven by the growing demand for cost-effective biologic drugs, especially in developing countries where access to expensive biologics is limited.
Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @
Top Companies Associated With The Biosimilars Market Report Are: Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy’s Laboratories, and Sanofi S.A.
The biosimilars market is primarily driven by two key factors – the rising demand for cost-effective biologics and increasing focus on research and development. With the ever-increasing burden of chronic diseases, there is a growing need for affordable treatment options. Biosimilars offer significant cost savings compared to their reference biologics, making them an attractive option for patients, healthcare providers, and government healthcare agencies.
Another major driver for this market is the increasing focus on research and development activities by pharmaceutical companies. The development of biosimilars requires extensive research, clinical trials, and regulatory approvals.
Market Drivers for Biosimilars Market
Cost-effectiveness and Growth Opportunities
Biosimilars have gained significant attention in the pharmaceutical industry due to their potential to offer cost-effective alternatives to existing biologic drugs. Biologic drugs are highly complex and costly to develop and manufacture, making them expensive for patients and healthcare systems. Biosimilars, on the other hand, can be developed at a lower cost using established manufacturing processes, resulting in reduced prices for patients. This cost-effectiveness is a major driver for the adoption of biosimilars, especially in emerging markets where access to expensive biologics is limited.
Furthermore, the biosimilars market offers immense growth opportunities. The expiry of patents for several blockbuster biologics has created a competitive landscape for biosimilar manufacturers. With the growing demand for affordable biologic therapies, biosimilars have the potential to capture a significant market share. The increasing prevalence of chronic diseases such as cancer, rheumatoid arthritis, and diabetes also provides an expanding patient pool for biosimilars. Consequently, pharmaceutical companies are investing in research and development of biosimilars to capitalize on these growth opportunities.
Supportive Regulatory Environment
The biosimilars market has been bolstered by a supportive regulatory environment that encourages the development and approval of biosimilar products. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established clear guidelines for the approval of biosimilars. These guidelines provide a streamlined pathway for manufacturers to demonstrate similarity to the reference biologic and ensure safety and efficacy.
The regulatory framework for biosimilars promotes competition and innovation while maintaining stringent standards for patient safety. This has created a favorable environment for biosimilar manufacturers, as they can navigate the regulatory process more efficiently and bring their products to market faster. The regulatory support for biosimilars has also attracted investments from pharmaceutical companies, leading to an increase in the number of players in the market and driving market growth.
Market Restraints for Biosimilars Market
Complexity and Manufacturing Challenges
Despite the cost advantages, developing and manufacturing biosimilars is a complex and challenging process. Biologic drugs are highly complex molecules produced using living organisms, making them difficult to reproduce exactly. Ensuring similarity to the reference biologic requires comprehensive analytical, biochemical, and functional testing, which can be time-consuming and resource-intensive.
Manufacturing biosimilars also presents challenges due to the inherent variability of biological systems. The production process must be tightly controlled to ensure consistency and quality of the final product. Additionally, the manufacturing facilities and equipment must meet stringent regulatory standards, such as Good Manufacturing Practices (GMP), further adding to the complexity and cost of producing biosimilars.
Patent Litigation and Market Saturation
Patent litigation is a major restraint for the biosimilars market. Reference biologic manufacturers often use patent protection to extend their exclusivity period, preventing or delaying the entry of biosimilars into the market. Legal battles over patents can be costly and time-consuming, hindering the timely launch of biosimilar products.
Moreover, the biosimilars market is becoming increasingly saturated with multiple players launching similar products. This intense competition can lead to price erosion and reduced profitability for biosimilar manufacturers. The need to invest in extensive clinical trials and demonstrate a high level of similarity to the reference biologic also adds to the overall cost of development and market entry.
Purchase This Premium Report And Get Up To 25 % Off @
Table of Contents with Major Points:
- Key Findings
- Definitions and Assumptions
- Definition of Biosimilars Market
- Market Dynamics
- Trends and Developments
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global Biosimilars Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
- Data Sources
The biosimilars market has significant drivers, such as cost-effectiveness and growth opportunities, along with a supportive regulatory environment. These factors are contributing to the increasing adoption and market growth of biosimilars. However, the complexity of development and manufacturing, as well as patent litigation and market saturation, pose as significant restraints for the market. Overcoming these challenges will be crucial for the continued growth and success of the biosimilars market.
We Offer Customized Report, Click @
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
Explore More Related Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Senior Client Partner – Business Development
Coherent Market Insights
Follow Us: LinkedIn | Twitter